CompletedNot Applicable

DECT in Imaging Patients With Solid Organ Cancer With Intracranial Metastasis

United States42 participantsStarted 2018-08-24

Plain-language summary

This trial studies how well dual energy computed tomography (DECT) works in imaging patients with solid organ cancer that has spread to the brain. Imaging techniques, such as DECT, may help find and diagnose tumor cells and find out how far the tumor cells have spread in the brain.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adult patient with pathology-proven solid organ cancer * MRI of the brain with contrast, positive for two or more metastatic lesions * One lesion with a single greatest diameter on contrast-enhanced MRI of 1 cm or greater * Planned treatment with stereotactic radiosurgery Exclusion Criteria: * Known allergy to iodine-based contrast agents * Patients with glomerular filtration rate (GFR) less than 30 or use of hemodialysis * If prior nephrectomy, GFR less than 60 * Prior central nervous system malignancy * Prior brain radiation * Pregnant women are excluded

What they're measuring

Best diagnostic performance of computed tomography (CT) reconstruction parameters

Timeframe: Up to 2 years

Accuracy of CT

Timeframe: Up to 2 years

Trial details

NCT IDNCT03685539

SponsorM.D. Anderson Cancer Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-08-29

View on ClinicalTrials.gov More Malignant Neoplasm trials